Drug Repositioning Bringing New Life To Shelved Assets And Existing Drugs Pdf
- and pdf
- Tuesday, April 20, 2021 4:11:50 AM
- 1 comment
File Name: drug repositioning bringing new life to shelved assets and existing drugs .zip
Phenotypic screening is a type of screening used in biological research and drug discovery to identify substances such as small molecules , peptides , or RNAi that alter the phenotype of a cell or an organism in a desired manner.
- ASSETS AND LIABILITIES OF DRUG REPOSITIONING
- Drug Repurposing, Rescue, and Repositioning
- ASSETS AND LIABILITIES OF DRUG REPOSITIONING
Wiley Online Library Sample Chapter.
ASSETS AND LIABILITIES OF DRUG REPOSITIONING
A new innovative peer-reviewed journal covering all aspects of drug repurposing, rescue, and repositioning including scientific, technical, legal, and regulatory developments. These special peer-reviewed collection of papers present techniques and tools for finding new uses for approved drugs — particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified. This authoritative, rapidly peer-reviewed special section will feature original papers, application-oriented technology reviews, and reports in methodology and technology application including:.
Prior abstract publications should be described in the form of a footnote to the manuscript title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc.
By submitting a manuscript to the Journal, the author s agree s to these conditions. Certain exceptions from this rule apply ex: some government employees, or work presented on behalf of governmental agencies. All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Drug Repurposing, Rescue, and Repositioning. For authors whose native language is not English, we suggest using a service that can aid in the translation and rewriting of material into correct and proper English usage.
The Publisher offers this service with a subsidy from the author prior to official submission contact AuthorServices liebertpub. All submissions are subject to peer review.
Authors are encouraged, but not required, to supply the names and email addresses of three to four individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be selected as a reviewer.
However, the review selection is ultimately at the discretion of the Editor. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a paper assumes responsibility and accountability for the results. Once a paper is accepted for publication, changes in authorship are NOT permitted.
Changes in authorship after publication are strictly prohibited. This designation should be determined at the time of submission. Additions to corresponding authors are not permitted after acceptance or in page proofs. Use Arabic numerals to number tables. Cost estimates are available from the Publisher upon request. The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form.
Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright. All manuscripts must comply with the privacy and confidentiality requirements outlined on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. When articles include reports of studies on human subjects, state in the Methods section that an appropriate institutional review board or ethics committee approved the study.
Authors who do not have formal ethics review committees should follow the principles of the Declaration of Helsinki. In the Methods section, state that informed consent was obtained from subjects specify written or verbal. The principal author must state that if animals were used experimentally, permission was obtained from the appropriate committee s , and that the animals were treated humanely and the standards conformed to those of current ethical animal research practices.
In addition, text and photographs should not reveal any identifying information unless it is essenti al for scientific purposes in which case, consent should be obtained. When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation institutional and national and with the Helsinki Declaration of , as revised in If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.
When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed. For more information, visit www. The Publisher will not accept corrections from multiple authors. Once a paper is accepted for publication, changes in authorship in the page proof stage are NOT permitted under any circumstance. REPRINTS Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected proofs to the Publisher.
Reprints ordered after an issue is printed will be charged at a substantially higher rate. Tel: ; Fax: ; Email: info liebertpub. All Mary Ann Liebert, Inc. Drug Repurposing, Rescue, and Repositioning is a single-blinded peer-reviewed journal. Upon submission, manuscripts are assessed by an editor for suitability for the journal.
For those that are deemed suitable, a minimum of two expert reviewers in the area of study will be selected to assess the scientific basis and significance of the manuscript. Editors and reviewers must maintain strict confidentiality of manuscripts during the peer-review process.
Sharing a manuscript in whole or in part, outside the scope of what is necessary for assessment, is impermissible prior to an accepted manuscript's official publication date. Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings during peer review unless it violates the privacy or confidentiality of human research subjects.
The Editor-in-Chief and Associate Editors will recuse themselves from participating in the review process of any manuscript in which there is a potential or actual competing interest. Drug Repurposing, Rescue, and Repositioning is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles.
All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content i. To avoid plagiarism, be sure to properly cite and reference all published works.
Deposition of a preprint on a preprint server is not considered as prior publication and will not impact consideration of any submitted manuscript. The journal strives to maintain a short, but thorough peer-review process. The average time in review is 21 days but the Editor will strive to expedite manuscript handling if circumstances dictate.
Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers. Authorship, as defined by the International Committee of Medical Journal Editors, is based on the following criteria:. Contributors who meet fewer than all four of the above criteria for authorship should not be listed as authors, but they should be acknowledged in the Acknowledgments section with a description of their contribution to the work.
There is a limit of 35 of authors permitted on a single submission, but in cases where there are 20 or more co-authors, Drug Repurposing, Rescue, and Repositioning recommends that a collective group or consortium name be provided and the individual authors listed in the Acknowledgements. One author should be designated as the corresponding author who will be responsible for communication between the authors and the journal editorial office s and publisher.
However, we recognize that some submissions call for more than one corresponding author to be noted. If the paper is accepted for publication, the full contact information for all desginated co-authors will be listed at the end of the article as per usual journal style. Working Groups or Teams may be listed in the manuscript byline, but the entire listing of names and affiliations should be included in the acknowledgment section of the manuscript.
Do not list the names in a footnote on the title page. It is permissible to list up to three authors as co-first authors, or as contributing equally to the work. Include a corresponding footnote, using the asterisk, on the title page that reads, "These authors contributed equally to this work and are considered to be co-first authors. Changes in authorship after submission or acceptance of a paper are strongly discouraged, but the editorial leadership recognizes that in certain circumstances, it may be required.
The journal's policy for such cases is as follows:. ATTENTION: To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:.
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, in the same form or substantially similar form, except in the form of a conference abstract. If work was presented at a conference, supply the name, date, and location of the meeting as a footnote on the title page of the submission. For authors whose native language is not English, we recommend using a service that will aid in the translation and rewriting of material into correct and proper English usage.
The Publisher offers this service for a fee prior to official submission. For more information, please contact: Editing liebertpub. Authors should identify as their institution s the facility where the work was performed and executed.
Corrections to affiliations or contact information due to relocation after publication is not permitted. Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate. When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee institutional and national , or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.
If the study is judged exempt from review, a statement from the committee is be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.
All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law —41 , effective December 13, All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.
Upon acceptance of any manuscript, all authors will receive an email with detailed instructions and a unique, author-specific link to access and complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors' email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications. Copyright forms may also be completed by logging in to the system using an author's credentials.
By submitting a manuscript to the Journal, the author s agree s to each of the above conditions. Drug Repurposing, Rescue, and Repositioning is a subscription-based peer-reviewed journal with Open Access options. Please contact our Open Access Manager to order open access for your article.
Learn more about open access publishing on our website. When reproducing copyrighted material such as figures, tables, or excerpted text, the author s of the submitted paper must obtain permission from the original publisher and submit it concurrently with the manuscript. The publication from which the figure or table is taken must be listed in the reference list.
Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, "Reprinted by permission from Jones et al. All permissions must be supplied at the time of submission. Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources. Mary Ann Liebert, Inc. A watermarked PDF version of the article not a Word document or any other editable version may be shared only with named, personal contacts at trusted news sources upon request.
Drug Repurposing, Rescue, and Repositioning
Embed Size px x x x x Sosei is a Japanese biopharmaceutical company that pioneered a unique open innovation business platform for drug reprofi ling using a sophisticated shared risk partnership model. Initiated in , its Drug Reprofi ling Platform DRP was actively driven by a core team of fi ve full time personnel, yielding a number of internal proj-ects based on its systematic approach to serendipitous new indications discov-ery. The full extent of its success is yet to be realized; however, at the time of writing, DRP has resulted in the identifi cation of dozens of off - target activities from a relatively small library of over 50 compounds, of which one asset, SD, has successfully completed Phase I clinical trials under current regula-tions after showing signifi cant activity in several models for its newly identifi ed indication neuropathic pain. Its lead pipeline product, NVA, is a drug that was already on the European Union EU market for the reduction of saliva secretion and has been repo-sitioned into a potential blockbuster for the treatment of chronic obstructive pulmonary disease COPD. NVA has now been licensed to Novartis along with the combination product with indacaterol, and both are in Phase III trials at the time of writing. The initial high hit rate in DRP can be attributed to the unique nature of the risk sharing model that provides a relatively small library of high quality compounds for screening against a variety of platform technologies, involving minimal upfront costs for all parties involved.
Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs. Edited by Michael J. Barratt and Donald E. Frail · Related.
ASSETS AND LIABILITIES OF DRUG REPOSITIONING
NCBI Bookshelf. Drug Repurposing and Repositioning: Workshop Summary. Turn recording back on. National Center for Biotechnology Information , U. Search term. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurology.
With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development. Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy. The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits.
The how's and why's of successful drug repositioning Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy. Drug Repositioning is divided into three parts: Part 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs. Part 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, and a look at the development of chemically modified analogs of approved agents. The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits. With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development.
Access to Document Link to publication in Scopus. About the Author Michael Barratt is an independent consultant and previously?
Drug Repurposing View all 8 Articles. For cancer indications, the primary goal of repurposed therapies is on efficacy, with less restriction on safety due to the immediate need to treat this patient population. This article provides insight into funding programs e. Finally, we describe the strategies that the pharmaceutical industry has previously employed to navigate regulatory considerations and successfully commercialize their drug products.
A new innovative peer-reviewed journal covering all aspects of drug repurposing, rescue, and repositioning including scientific, technical, legal, and regulatory developments. These special peer-reviewed collection of papers present techniques and tools for finding new uses for approved drugs — particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified. This authoritative, rapidly peer-reviewed special section will feature original papers, application-oriented technology reviews, and reports in methodology and technology application including:. Prior abstract publications should be described in the form of a footnote to the manuscript title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc.
- Беккер взял подушку с соседней койки и помог Клушару устроиться поудобнее. Старик умиротворенно вздохнул. - Так гораздо лучше… спасибо .
Человек улыбнулся: охота становилась интересной. Беккер здесь… Я чувствую, что. Он двигался методично, обходя один ряд за другим. Наверху лениво раскачивалась курильница, описывая широкую дугу.
- Посмотрим, чем ты тут занимаешься. Окинув быстрым взглядом находящееся за стеклом помещение шифровалки, Сьюзан включила кнопку яркости. Вспыхнувший экран был совершенно пуст. Несколько этим озадаченная, она вызвала команду поиска и напечатала: НАЙТИ: СЛЕДОПЫТ Это был дальний прицел, но если в компьютере Хейла найдутся следы ее программы, то они будут обнаружены.
Кнопка на полу привела ее в движение, и дверь, издав шипящий звук, отъехала в сторону. Чатрукьян ввалился в комнату. - Коммандер… сэр, я… извините за беспокойство, но монитор… я запустил антивирус и… - Фил, Фил, - нехарактерным для него ласковым тоном сказал Стратмор. - Потише и помедленнее. Что случилось.